ONON inventory forecast 2025 refers back to the predicted efficiency of Onconova Therapeutics, Inc. (ONON) inventory over the following few years. It will be important for traders to think about inventory forecasts as they’ll present useful insights into the potential progress and profitability of an organization.
ONON is a clinical-stage biopharmaceutical firm targeted on discovering and creating novel most cancers therapies. The corporate’s lead product candidate, rigosertib, is a small molecule that targets a number of signaling pathways concerned in most cancers progress and survival. Rigosertib is at present being evaluated in a number of medical trials for the remedy of assorted varieties of most cancers, together with lung most cancers, breast most cancers, and pancreatic most cancers.
